A Study to Evaluate the Safety and Activity of SAR448501/DR-0201 in Patients With Autoimmune Rheumatic Diseases

NCT06647069 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

62

Enrollment

INDUSTRY

Sponsor class

Conditions

Systemic Lupus Erythematosus (SLE)
Rheumatoid Arthritis (RA)

Interventions

DRUG: SAR448501

Sponsor

Sanofi